Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) - Drugs In Development, 2021

August 2021 | 675 pages | ID: C0C1032E2C8CEN
Global Markets Direct

Abstracts

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Drugs In Development, 2021, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 31, 22, 7, 90, 22 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 3 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Chronic Obstructive Pulmonary Disease (COPD) - Overview
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestonesh
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by 3SBio Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Acahealth Pharma and Biotech Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aeon Respire Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AIBIOS Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apollo Therapeutics LLC, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aquilon Pharmaceuticals SA, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Arrowhead Pharmaceuticals Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Atriva Therapeutics GmbH, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AusBio Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Avidin Biotechnology Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axolo Pharma Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bai Shuo Beijing Pharmaceutical Technology Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by BioMarck Pharmaceuticals Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biosion Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotoxtech Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by INVENT Pharmaceuticals Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ionis Pharmaceuticals Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Joincare Pharmaceutical Group Industry Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KBP Biosciences Holdings Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kither Biotech Srl, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Korea United Pharm Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Koutif Therapeutics LLC, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Kirin Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Landos Biopharma Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Laurel Therapeutics, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by LTT Bio-Pharma Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mariposa Health Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MD Healthcare Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MDimune Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mereo Biopharma Group Plc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Meridigen Biotech Co Ltd, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Metagone Biotech Inc, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, 2021
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021